Table 1.
Comparison of fibrotic markers and liver stiffness in patients with ALF, CHB and cirrhosis
| ALFa | CHB | P 1 | Cirrhosis | P 2 | |
|---|---|---|---|---|---|
| HA (μg/L) | >800 | 179.20 (25.0–591.3) | 0.000 | 243.55 (27.4–800) | 0.000 |
| PCIII (μg/L) | 386.91 (127.5 to >640) | 170.50 (64.7–467.3) | 0.020 | 115.05 (40–280.1) | 0.003 |
| CIV (μg/L) | 194.60 (103.8–312.6) | 84.40 (32.1–127.5) | 0.000 | 86.45 (49.7–217.6) | 0.000 |
| LN (μg/L) | 87.70 (40–170.05) | 73.80 (40–177.1) | 0.344 | 97.60 (40–124.3) | 0.977 |
| LSM (kpa) | 30.80 (14.3–75) | 11.80 (4.1–27.7) | 0.001 | 14.30 (5.3–55.1) | 0.026 |
a
Progression stage of ALF.
P 1 : P value for comparison between patients with ALF and CHB.
P 2 : P value for comparison between patients with ALF and cirrhosis.
ALF Acute liver failure, CHB chronic hepatitis B, HA hyaluronic acid, PCIII procollagen III, CIV collagen IV, LN Laminin, LSM liver stiffness mesurment.